CTSA INFRASTRUCTURE FOR AIDS RESEARCH

该子项目是对CTSA供资的百分比的估计， 用于广泛的研究领域（艾滋病研究，儿科研究，或 临床试验）。 列出的总成本仅为CTSA金额的估算 基础设施走向这一领域的研究，而不是直接提供资金， 向子项目或子项目工作人员提供NCRR补助金。 我们建议建立一个北部和中部得克萨斯州临床和转化科学倡议（NCTCTSI），这将是由得克萨斯大学西南医学院在达拉斯，并将包括对抗疗法和骨病，牙科，护理，药学，公共卫生，工程和计算机科学-这已经形成了一个由路线图K12奖支持的高度功能性的关系。我们已经建立了一个临床科学系，由所有参与学校的教师支持，并将作为我们CTSA的学术之家。该部门提供学术任命的临床和翻译研究人员和教师的专业知识和研究是集中在方法学科共同所有临床研究-以促进“多学科团队建设和解决问题。NCTCTSI将建立在现有的K30，M01和路线图K12奖项支持的国家认可的计划基础上，并将整合众多机构的优势，提供12个高度创新和完全集成的关键功能：（1）为临床和转化研究建立一个独特的学术家园;（2）转变文化：研究者的发展和认可;（3）研究教育、培训和职业发展;（4）生物医学信息学;（5）激发新的转化思想和方法;（6）支持试点和合作研究;（7）研究开发：设计、统计和伦理;（8）科学审查和评估;（9）监管知识和支持;（10）参与者和临床互动资源;（11）社区参与;（12）转化技术和资源。特别的优势是：（1）参与机构对该倡议的大量财政承诺;（2）一个目前致力于NIH许多目标的成熟的学术和文化之家;（3）200多名成熟的临床和翻译研究人员，他们将担任教师和导师;（4）采用高度创新的方法，整合关键职能，在多学科学术界成员之间建立联系;（5）由国际知名医院照顾的庞大和多样化的病人基础（这是这一倡议的坚定支持者）;（6）> 1.5亿美元的年度同行评审拨款支持临床研究;（7）一流的基础设施，以支持临床和转化研究;以及（8）具有时间、经验和承诺的项目领导，以确保该倡议的成功。这些优势的协调综合将使NCTCTSI能够改善我们社区的健康，并为国家CTSA联盟做出贡献，从而有助于确定有利于全国临床和转化研究的最佳实践。

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. We propose to establish a North and Central Texas Clinical and Translational Science Initiative (NCTCTSI), which will be led by the University of Texas Southwestern Medical School at Dallas and will include many of the nation's leading schools of allopathic and osteopathic medicine, dentistry, nursing, pharmacy, public health, engineering and computer science - which have already formed a highly functional relationship supported by a Road map K12 award. We have established a Department of Clinical Sciences, which is supported by faculty from all participating schools and which will serve as the academic home for our CTSA. The Department provides academic appointments to clinical and translational investigators and to faculty whose expertise and research is focused on methodological disciplines common to all clinical research - in order to promote 'multidisciplinary team building and problem solving. The NCTCTSI will build on existing nationally- recognized programs supported by K30, M01 and Roadmap K12 awards and will integrate numerous institutional strengths to offer 12 highly innovative and fully integrated key functions: (1) building a unique academic home for clinical and translational research; (2) transforming a culture: investigator development and recognition; (3) research education, training and career development; (4) biomedical informatics; (5) stimulating novel translational ideas and methodologies; (6) support for pilot and collaborative studies; (7) research study development: design, statistics and ethics; (8) scientific review and evaluation; (9) regulatory knowledge and support; (10) participant and clinical interactions resources; (11) community engagement; and (12) translational technologies and resources. Particular strengths are: (1) a substantial financial commitment of participating institutions to the Initiative; (2) an established academic and cultural home that currently addresses many of the goals of the NIH; (3) > 200 established clinical and translational investigators who will act as faculty and mentors; (4) a highly innovative approach to integrating key functions that will act to create bonds among the members of a multidisciplinary academic community; (5) a large and medically diverse patient base cared for by internationally-renowned hospitals (which are strong supporters of this initiative); (6) > $150 million in annual peer-reviewed grant support for clinical studies; (7) superb infrastructure to support clinical and translational research; and (8) program leadership with the time, experience and commitment to ensure the success of the Initiative. The coordinated synthesis of these strengths will allow the NCTCTSI to improve the health of our community and to contribute to the national CTSA consortium and thus help to identify best practices that will benefit clinical and translational research throughout the nation.